A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Latest Information Update: 08 Jun 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 24 Sep 2005 New trial record.